- Home
- AKRO vs EXTR Comparison
AKRO vs EXTR Comparison
Compare AKRO & EXTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- EXTR
- Stock Information
- Founded
- AKRO 2017
- EXTR 1996
- Country
- AKRO United States
- EXTR United States
- Employees
- AKRO N/A
- EXTR N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- EXTR Telecommunications Equipment
- Sector
- AKRO Health Care
- EXTR Telecommunications
- Exchange
- AKRO Nasdaq
- EXTR Nasdaq
- Market Cap
- AKRO 3.9B
- EXTR 2.4B
- IPO Year
- AKRO 2019
- EXTR 1999
- Fundamental
- Price
- AKRO $51.69
- EXTR $17.29
- Analyst Decision
- AKRO Strong Buy
- EXTR Strong Buy
- Analyst Count
- AKRO 6
- EXTR 7
- Target Price
- AKRO $82.50
- EXTR $18.57
- AVG Volume (30 Days)
- AKRO 1.6M
- EXTR 1.2M
- Earning Date
- AKRO 08-08-2025
- EXTR 08-06-2025
- Dividend Yield
- AKRO N/A
- EXTR N/A
- EPS Growth
- AKRO N/A
- EXTR N/A
- EPS
- AKRO N/A
- EXTR N/A
- Revenue
- AKRO N/A
- EXTR $1,089,717,000.00
- Revenue This Year
- AKRO N/A
- EXTR $3.47
- Revenue Next Year
- AKRO N/A
- EXTR $7.79
- P/E Ratio
- AKRO N/A
- EXTR N/A
- Revenue Growth
- AKRO N/A
- EXTR N/A
- 52 Week Low
- AKRO $21.34
- EXTR $10.10
- 52 Week High
- AKRO $58.40
- EXTR $19.24
- Technical
- Relative Strength Index (RSI)
- AKRO 45.35
- EXTR 49.80
- Support Level
- AKRO $50.13
- EXTR $17.83
- Resistance Level
- AKRO $53.60
- EXTR $18.81
- Average True Range (ATR)
- AKRO 2.03
- EXTR 0.45
- MACD
- AKRO -0.83
- EXTR -0.12
- Stochastic Oscillator
- AKRO 6.37
- EXTR 36.67
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.